Chronic Urticaria – Landscape & Forecast – Disease Landscape & Forecast (G7)
The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, which are prescribed for both chronic inducible urticaria (CIndU) and chronic spontaneous urticaria (CSU). However, both drug classes can have serious side effects, and many patients still struggle to control their lesions. The approvals of Xolair and Dupixent in the major markets have provided treatment options for some of these patients, and clinical trials of additional biological therapies are under way. With only one biological drug approved for urticaria in the G7 countries, the most important factors driving prescribing decisions remain unknown, and many of the unmet needs in this market remain unfulfilled.
Questions answered
- What is the physician perspective on antihistamines for chronic urticaria? How frequently are these therapies prescribed?
- How do physicians diagnose and treat chronic urticaria, and how does treatment differ between specialists? Are CIndU and CSU treated similarly, or is the treatment algorithm distinct?
- Which therapies are expected to have the biggest impact on the chronic urticaria market forecast? Will emerging therapies shift the treatment algorithm, or will biologics remain later-line treatments?
- How does Novartis / Roche’s Xolair—approved for CSU—perform, and how will emerging biologics and targeted oral agents compare?
Geography: United States, EU5, Japan
Primary research: Country-specific interviews with thought-leading dermatologists and allergists, survey data collected for this and other Clarivate research
Epidemiology: Number of chronic urticaria patients by country, including diagnosed and drug-treated chronic spontaneous urticaria and chronic inducible urticaria patients
Forecast: 10-year, annualized, drug-level sales and patient share of key chronic urticaria therapies through 2034, segmented by brands / generics and epidemiological subpopulations
Drug treatments: Coverage of key current and late-phase emerging therapies
Product description
Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
- Gauge the commercial outlook and impact of key market events.
Table of contents
- Chronic Urticaria - Landscape & Forecast - Disease Landscape & Forecast (G7)
- Executive Summary
- Key Updates
- Market Forecast
- Disease Context
- Epidemiology
- Key takeaways
- Diagnosed 12-month prevalent cases of chronic urticaria
- Total 12-month prevalent cases of chronic spontaneous urticaria
- Total 12-month prevalent cases of chronic inducible urticaria
- Total 12-month prevalent cases of chronic spontaneous and inducible urticaria (overlap)
- Diagnosed and drug-treated populations
- Key takeaways
- Current Treatment
- Emerging Therapies
- Drug Pipeline
- Appendix
- Executive Summary
